利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

201 条记录 (耗时 0.02 秒)

    CARRIER MATRIX COMPRISING DODECIN PROTEIN
    113.
    发明公开
    CARRIER MATRIX COMPRISING DODECIN PROTEIN 审中-公开

    公开(公告)号：EP3845553A1

    公开(公告)日：2021-07-07

    申请号：EP19220117.6

    申请日：2019-12-30

    申请人： Johann Wolfgang Goethe-Universität ,  EMBL European Molecular Biology Laboratory

    发明人： GRININGER, Martin ,  BOURDEAUX, Florian ,  GOESSNER, Ines ,  REMANS, Kim ,  BESIR, Hüseyin

    IPC分类号： C07K14/195

    摘要： The present invention relates to a carrier conjugate comprising at least one dodecin protein unit conjugated with at least one hapten and/or immunogenic and/or enzymatically active moiety. Further, the invention relates to a method for producing said conjugate and a method for producing antibodies that specifically binds to a hapten and/or immunogenic moiety of the conjugate, and to a method for performing enzymatic or diagnostic assays in vitro using said conjugate. Moreover, the invention relates to the use of said conjugate for producing antibodies that specifically bind to the epitope or epitopes contained in the moiety of said conjugate and use of said conjugate for performing enzymatic or diagnostic assays in vitro.

    PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF INFECTIONS AND ANTIBACTERIAL-INDUCED DYSFUNCTIONS
    118.
    发明公开
    PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF INFECTIONS AND ANTIBACTERIAL-INDUCED DYSFUNCTIONS 审中-公开

    公开(公告)号：EP3560489A1

    公开(公告)日：2019-10-30

    申请号：EP18169989.3

    申请日：2018-04-27

    申请人： European Molecular Biology Laboratory

    发明人： Gontao Brochado, Ana Rita ,  Typas, Athanasios ,  Göttig, Stephan

    IPC分类号： A61K31/11 ,  A61K31/12 ,  A61K31/395 ,  A61K31/7036 ,  A61P31/04

    摘要： The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.

    REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME
    119.
    发明公开
    REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME 审中-公开

    公开(公告)号：EP3524237A1

    公开(公告)日：2019-08-14

    申请号：EP18156520.1

    申请日：2018-02-13

    申请人： European Molecular Biology Laboratory

    发明人： PRUTEANU, Mihaela ,  MAIER, Lisa ,  KUHN, Michael ,  BORK, Peer ,  TYPAS, Athanasios ,  PATIL, Kiran Raosaheb ,  ZELLER, Georg

    IPC分类号： A61K31/137 ,  A61K31/4422 ,  A61P31/04

    摘要： The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and/or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans. Particularly interesting compounds of this invention are effective against pathobiological species such as Clostridium difficile, Clostridium perfingens, Fusobacterium nucleatum, and an enterotoxigenic strain of Bacteroides fragilis. Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bacterial species. Such compounds are useful for broad-spectrum antibiotic therapies of infections with unknown causative infecting bacterial species. Both types of compounds, especially the ones with narrow-spectrum antibacterial activity, can further be used for modulating the microbiome composition and targeting species associated with dysbiosis and disease.